GET DAILY SIGNALSWhy Is Johnson & Johnson (JNJ) Stock Down -5.15% Today?
Key Takeaways
- JNJ shares fell roughly 5.15% in Tuesday's session, extending losses that began in premarket trading.
- The primary catalyst was the company's third-quarter 2026 earnings report, which beat on profit but revealed weakness in its medical technology (MedTech) division.
- MedTech sales rose only 2.5% and missed Wall Street's target, with all four segments underperforming.
- Geopolitical headwinds — notably the Middle East conflict, European austerity, and China pricing pressure — weighed on international device sales.
- Investors also digested a steep GAAP profit decline tied to a talc litigation settlement charge and management's signal that it may spin off its orthopedics business.
Opening Summary
Johnson & Johnson (JNJ), the healthcare giant spanning pharmaceuticals, medical devices, and consumer-adjacent health products, saw its stock slide sharply on Tuesday after reporting mixed third-quarter results. Shares were trading around $250.16, down from a prior close of $263.73 — a decline of roughly 5.15%. Despite a profit beat and an upwardly revised full-year outlook, markets focused on a disappointing showing in the company's medical technology segment, sending the stock lower in a classic earnings-driven "sell the news" reaction.
Earnings Beat Overshadowed by MedTech Miss
The headline numbers looked solid. Johnson & Johnson posted third-quarter revenue of $25.4 billion, up 5.9% year over year and roughly in line with consensus, while adjusted earnings of $2.59 per share topped Wall Street's estimate of about $2.52–$2.54. Pharmaceutical sales climbed 7.7% to $16.76 billion, powered by standout growth in immunology and oncology products. Sales of Tremfya, the autoimmune drug positioned to replace the patent-expiring blockbuster Stelara, surged 68%.
Yet those strengths could not offset the market's disappointment in MedTech. The division generated $8.64 billion, below the roughly $8.74 billion analysts had expected, with cardiovascular, orthopedics, surgery, and vision all underperforming. The result, on top of a prior-quarter stumble, reinforced concerns that the company's device business is lagging even as its pharmaceutical arm accelerates.
Geopolitics and International Pressure
Management pointed to a cluster of external headwinds crimping device demand overseas. Chief Financial Officer Joe Wolk said the Middle East conflict had diverted government budgets in premium healthcare markets such as Kuwait, the UAE, and Saudi Arabia toward defense spending. European austerity measures and pricing pressure in China compounded the drag, leaving international MedTech sales essentially flat. Separately, sales of Abiomed's Impella heart pumps remained subdued following a UK study that raised questions about their use in certain high-risk procedures.
Talc Charge and Orthopedics Spinoff
The quarter also featured notable one-time items. Reported net income fell to $210 million from roughly $5.15 billion a year earlier, largely reflecting a charge tied to the proposed resolution of longstanding talc litigation, alongside the acquisition of Firefly Bio and a collaboration with Sail Biomedicines. On an adjusted basis, net income declined a more modest 6.8%. Meanwhile, management signaled it is leaning toward spinning off its orthopedics business — the DePuy Synthes hips-and-knees franchise — rather than pursuing a sale, adding another layer of uncertainty to the company's device strategy.
Market Context and Trading Activity
The decline came on elevated trading volume typical of an earnings-day move, as investors repositioned following the report. The reaction also reflected the stock's demanding setup entering the quarter: JNJ had risen more than 25% over the prior year and was trading near record highs, leaving little room for even a modest segment-level miss. As the first major pharmaceutical name to report, Johnson & Johnson's results set a cautious tone for the broader healthcare complex ahead of upcoming releases from peers.
What Comes Next for JNJ
Investors will now watch whether management's promised "focused action" in MedTech translates into improved device growth, and how the potential orthopedics separation unfolds. The pharmaceutical business remains the clear engine, but its momentum must continue to counterbalance device softness and the ongoing erosion of Stelara revenue from generic competition. Macro factors — the trajectory of Middle East tensions, European fiscal policy, and China pricing dynamics — will also shape the international device outlook. Any further clarity on the talc litigation resolution and the full-year guidance trajectory could move sentiment in either direction.
Trending AI Robots
Traders seeking a systematic edge can explore Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to find approaches aligned with their own goals. Explore the Trending AI Robots to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JNJ in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 21 of 47 cases over the following month. The odds of a continued upward trend are 45%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement